Development of a 5-mRNAsi-related gene signature to predict the prognosis of colon adenocarcinoma

被引:1
作者
Huang, Haifu [1 ]
Lu, Lin [1 ]
Li, Yaoxuan [1 ]
Chen, Xiumei [1 ]
Li, Meng [1 ]
Yang, Meiling [1 ]
Huang, Xuewu [2 ]
机构
[1] Guangzhou Univ Tradit Chinese Med, Shenzhen Hosp, Dept Hematol & Oncol, Shenzhen, Peoples R China
[2] Guangzhou Univ Tradit Chinese Med, Affiliated Hosp 1, Tumor Ctr, Guangzhou, Peoples R China
来源
PEERJ | 2023年 / 11卷
关键词
Cancer stem cells; Colon adenocarcinoma; Prognosis; Clusters; RiskScore; Immune; MYELOID-LEUKEMIA; CANCER; EXPRESSION; MICROENVIRONMENT; PATHWAY; CELLS;
D O I
10.7717/peerj.16477
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Aim. To create a prognosis model based on mRNA-based stem index (mRNAsi) for evaluating the prognostic outcomes of colon adenocarcinoma (COAD).Background. Generation of heterogeneous COAD cells could be promoted by the self-renewal and differentiation potential of cancer stem cells (CSCs). Biomarkers contributing to the development of COAD stem cells remained to be discovered.Objective. To develop and validate an mRNAsi-based risk model for estimating the prognostic outcomes of patients suffering from COAD. Methods. Samples were collected from Rectal Adenocarcinoma (TCGA-READ) PanCancer Atlas datasets, The Cancer Genome Atlas Colon Adenocarcinoma (TCGACOAD), and the GSE87211 dataset. MRNAsi was calculated by one-class logistic regression (OCLR) algorithm. Under the criterion of correlation greater than 0.4, genes related to mRNAsi were screened and clustered. Meanwhile, differentially expressed genes (DEGs) between molecular subtypes were identified to establish a risk model. According to the median risk score value for immunotherapy and results from immune cell infiltration and clinicopathological analyses, clusters and patients were divided into high-RiskScore and low-RiskScore groups. Cell apoptosis and viability were detected by flow cytometer and Cell Counting Kit-8 (CCK-8) assay, respectively.Results. A negative correlation between mRNAsi and clinical stages was observed. Three clusters of patients (C1, C2, and C3) were defined based on a total of 165 survivalrelated mRNAsi genes. Specifically, C1 patients had greater immune cell infiltration and a poorer prognosis. A 5-mRNAsi-gene signature (HEYL, FSTL3, FABP4, ADAM8, and EBF4) served as a prediction index for COAD prognosis. High-RiskScore patients had a poorer prognosis and higher level of immune cell infiltration. In addition, the five genes in the signature all showed a high expression in COAD cells. Knocking down HEYL promoted COAD cell apoptosis and inhibited viability.Conclusion. Our mRNAsi risk model could better predict the prognosis of COAD patients.
引用
收藏
页数:23
相关论文
共 34 条
  • [1] Conserved pan-cancer microenvironment subtypes predict response to immunotherapy
    Bagaev, Alexander
    Kotlov, Nikita
    Nomie, Krystle
    Svekolkin, Viktor
    Gafurov, Azamat
    Isaeva, Olga
    Osokin, Nikita
    Kozlov, Ivan
    Frenkel, Felix
    Gancharova, Olga
    Almog, Nava
    Tsiper, Maria
    Ataullakhanov, Ravshan
    Fowler, Nathan
    [J]. CANCER CELL, 2021, 39 (06) : 845 - +
  • [2] Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks
    Blanche, Paul
    Dartigues, Jean-Francois
    Jacqmin-Gadda, Helene
    [J]. STATISTICS IN MEDICINE, 2013, 32 (30) : 5381 - 5397
  • [3] The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments
    Bustin, Stephen A.
    Benes, Vladimir
    Garson, Jeremy A.
    Hellemans, Jan
    Huggett, Jim
    Kubista, Mikael
    Mueller, Reinhold
    Nolan, Tania
    Pfaffl, Michael W.
    Shipley, Gregory L.
    Vandesompele, Jo
    Wittwer, Carl T.
    [J]. CLINICAL CHEMISTRY, 2009, 55 (04) : 611 - 622
  • [4] Cherciu Irina, 2014, Curr Health Sci J, V40, P153, DOI 10.12865/CHSJ.40.03.01
  • [5] The Emerging Role of Lymphocyte Activation Gene 3 in the CancerImmunotherapy br
    Cui, Xue
    Peng, Min
    Chen, Honglei
    [J]. ONCOLOGIE, 2022, 24 (04) : 665 - 678
  • [6] Personalizing Colon Cancer Adjuvant Therapy: Selecting Optimal Treatments for Individual Patients
    Dienstmann, Rodrigo
    Salazar, Ramon
    Tabernero, Josep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (16) : 1787 - +
  • [7] Synthesis, Biological Investigation and Docking Study of Novel Chromen Derivatives as Anti-Cancer Agents
    Dube, Pritam N.
    Sakle, Nikhil S.
    Dhawale, Sachin A.
    More, Shweta A.
    Mokale, Santosh N.
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2019, 19 (09) : 1150 - 1160
  • [8] Statistical predictions with glmnet
    Engebretsen, Solveig
    Bohlin, Jon
    [J]. CLINICAL EPIGENETICS, 2019, 11 (01)
  • [9] pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels
    Geeleher, Paul
    Cox, Nancy
    Huang, R. Stephanie
    [J]. PLOS ONE, 2014, 9 (09):
  • [10] Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer
    Hu, Jiao
    Yu, Anze
    Othmane, Belaydi
    Qiu, Dongxu
    Li, Huihuang
    Li, Chao
    Liu, Peihua
    Ren, Wenbiao
    Chen, Minfeng
    Gong, Guanghui
    Guo, Xi
    Zhang, Huihui
    Chen, Jinbo
    Zu, Xiongbing
    [J]. THERANOSTICS, 2021, 11 (07): : 3089 - 3108